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OBSERVATIONS
PrognosticRelevance
of Hypoglycemia
Following an Oral
Glucose Challenge
for Cystic Fibrosis–
Related Diabetes
A
n annual oral glucose tolerance test
(OGTT) has become part of stan-
dard care in cystic ﬁbrosis (CF) to
screen for CF-related diabetes (CFRD) in
patientsolder than 10 years of age (1).Up
to 15% of patients with CF develop hy-
poglycemia during an OGTT (2), and
there is some discussion whether such a
response indicates an increased risk for
the development of CFRD. In fact, a re-
active hypoglycemia has been considered
as an early stage of CFRD (3). However,
t h ep r o g n o s t i cv a l u eo fs u c har e a c t i v e
hypoglycemia with respect to future glu-
cose control has never been studied.
Based on a delayed insulin secretion in
CF, which might be relevant to both a
hypoglycemic as well as a hyperglycemic
response to a glucose challenge (4), we
hypothesized that the hypoglycemic re-
sponse to a glucose challenge could
indicate a stage preceding CFRD. The
objective of this study therefore was to
determine the prognosticvalueofahypo-
glycemic response during an OGTT for
future impaired glucose tolerance (IGT)
and CFRD.
We retrospectively analyzed data col-
lected between 2001 and 2009 from
1,779 patients who participated in a lon-
gitudinal prospective study on “Early Di-
agnosis of Diabetes Mellitus in Patients
with Cystic Fibrosis.” All patients were
10 years of age or older and performed
standardized OGTTs (5), at least on an
annual basis. OGTT results were cate-
gorized following the World Health Or-
ganization guidelines (5). All patients
included into the current analysis (n 5
841) had at least two valid OGTTs each
and a normal glucose tolerance to the ﬁrst
challenge. The patients with normal glu-
cose tolerance were divided into two sub-
groups:onegroupwithanentirelynormal,
nonhypoglycemic plasma glucose level
2 h after the challenge (3.3–7.7 mmol/L;
60–139 mg/dL) and one group with a hy-
poglycemic 2-h plasma glucose level
(,3.3 mmol/L; ,60 mg/dL). The groups
were compared regarding the incidence of
IGT and CFRD at the last available OGTT
using x
2 statistics. A hypoglycemic re-
sponse to the ﬁrst oral glucose challenge
was observed in53ofthe 841participants
(6.3%). There was no difference between
patients with an entirely normal, nonhy-
poglycemic response (n 5 788) and those
with a hypoglycemic response to the ﬁrst
OGTT in the incidence of CFRD (10.3 vs.
13.2%) or IGT (12.9 vs. 11.3%) at the last
OGTT 3.5 6 1.8 years later. Likewise,
groups did not differ in age, sex distribu-
tion, BMI, and time interval between ﬁrst
and last OGTT.
The 7% incidence of hypoglycemia
observed in our study was lower than the
15% previously reported for CF patients
(2). A hypoglycemic response to an
OGTT does not indicate a risk for future
CFRDor IGT,atleast notinthefollowing
3.5years.Thisﬁndingisincontrasttoour
hypothesis. We had expected that a dys-
regulation of insulin secretion in CF
would be responsible for reactive hypo-
glycemia and also—at least in part—for
glucose intolerance and overt diabetes in
this disease. Our data indicate that the
mechanisms underlying reactive hypo-
glycemia are different from those in-
volved in glucose intolerance or CFRD
in CF.
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